Matulonis Ursula A, Lorusso Domenica, Oaknin Ana, Pignata Sandro, Dean Andrew, Denys Hannelore, Colombo Nicoletta, Van Gorp Toon, Konner Jason A, Marin Margarita Romeo, Harter Philipp, Murphy Conleth G, Wang Jiuzhou, Noble Elizabeth, Esteves Brooke, Method Michael, Coleman Robert L
Ursula A. Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA; Domenica Lorusso, MD, Fondazione Policlinico Universitario A. Gemelli, IRCCS and Catholic University of Sacred Heart, Rome, Italy; Ana Oaknin, MD, PhD, Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Sandro Pignata, MD, Istituto Nazionale Tumori di Napoli Fondazione G Pascale IRCCS, Naples, Italy; Andrew Dean, MD, WA Medical Oncology St John of God Subiaco Hospital, Subiaco, WA, Australia; Hannelore Denys, MD, PhD, Ghent University Hospital, Ghent, Belgium; Nicoletta Colombo, MD, European Institute of Oncology IRCCS, Milan, Italy and University of Milan-Bicocca, Milan, Italy; Toon Van Gorp, MD, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium; Jason A. Konner, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Margarita Romeo Marin, MD, Institut Català d'Oncologia, Badalona, Spain; Philipp Harter, MD, Ev. Kliniken Essen-Mitte, Essen, Germany; Conleth G. Murphy, MD, Bon Secours Hospital and Cancer Trials, Cork, Ireland; Jiuzhou Wang, PhD; Elizabeth Noble, BS; Brooke Esteves, BS; and Michael Method, MD, ImmunoGen Inc, Waltham, MA; and Robert L. Coleman, MD, US Oncology Research, Texas Oncology, The Woodlands, TX.
J Clin Oncol. 2023 Oct 10;41(29):4705-4706. doi: 10.1200/JCO.23.00752. Epub 2023 Aug 3.